SAR447971 first-in-human study

2026-525333-22-00 Protocol SAD20411-MAD20412 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 22 May 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol SAD20411-MAD20412

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 134
Countries 1
Sites 1

Hidradenitis

Key facts

Sponsor
Sanofi-Aventis Recherche & Developpement
Participant type
Healthy volunteers, Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
22 May 2026 → ongoing
Decision date (initial)
2026-05-20
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2026-525333-22-00
WHO UTN
U1111-1334-4747

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Hidradenitis

VersionLevelCodeTermSystem organ class
20.0 PT 10020040 Hidradenitis 100000004858

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sanofi-Aventis Recherche & Developpement

Sponsor organisation
Sanofi-Aventis Recherche & Developpement
Address
13 Quai Jules Guesde
City
Vitry Sur Seine
Postcode
94400
Country
France

Scientific contact point

Organisation
Sanofi-Aventis Recherche & Developpement
Contact name
Clinical Sciences and Operations

Public contact point

Organisation
Sanofi-Aventis Recherche & Developpement
Contact name
Clinical Sciences and Operations

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 134 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Centre for Human Drug Research
Immunology, Zernikedreef 8, 2333 CL, Leiden

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2026-05-22 2026-05-26

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-03-30 Netherlands Acceptable
2026-05-20
2026-05-20